CD19 CAR-T cell therapy for relapsed and refractory (R/R) B-cell lymphoma has achieved an unprecedented response rate and durable remission. Then CAR-T cell therapy has been rapidly approved at home and abroad for the treatment of more than the second lines of R/R large B-cell lymphoma. Subsequently, its indication of mantle cell lymphoma and follicular lymphoma has been approved. CAR-T cell therapy has changed the treatment paradigm of B-cell lymphoma. With its wide application in the real world and the long follow-up time, some patients can be clinically cured by CAR-T cell therapy, which further confirms the leading role of CAR-T cell therapy in high-risk lymphoma. Yet, CAR-T cell therapy still has many problems, such as patient selection and treatment timing, advantages and disadvantages in comparison with existing treatments. At the same time, it also faces many challenges, such as further improving the safety and effectiveness with bridging therapy and combination therapy, and CAR-T cell has not yet shown a positive effect on Hodgkin’s lymphoma and T-cell lymphoma. In this review, we summarized the current progress in CAR-T cell therapy for lymphoma, and briefly discussed the related problems and their solutions.